Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:DAWN NASDAQ:DCPH NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$61.30+0.6%$61.79$43.70▼$86.53$1.94B-1.547,362 shs44,334 shsDAWNDay One Biopharmaceuticals$6.40$6.59$6.08▼$16.76$648.72M-1.271.17 million shs1.04 million shsDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shs600 shsLGNDLigand Pharmaceuticals$141.12+1.5%$112.10$90.29▼$143.13$2.68B0.84120,761 shs427,636 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+0.62%-3.59%+1.36%+5.00%+21.80%DAWNDay One Biopharmaceuticals0.00%-7.65%+1.27%-12.69%-57.28%DCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%LGNDLigand Pharmaceuticals+1.45%+11.19%+23.71%+32.54%+41.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLTEBelite Bio2.1049 of 5 stars3.52.00.00.02.10.80.6DAWNDay One Biopharmaceuticals2.8978 of 5 stars3.63.00.00.03.12.50.0DCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALGNDLigand Pharmaceuticals3.6503 of 5 stars1.51.00.04.42.83.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.6757.69% UpsideDAWNDay One Biopharmaceuticals 3.14Buy$29.00353.13% UpsideDCPHDeciphera Pharmaceuticals 0.00N/AN/AN/ALGNDLigand Pharmaceuticals 3.00Buy$147.174.28% UpsideCurrent Analyst Ratings BreakdownLatest DCPH, LGND, DAWN, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$4.72 per shareN/ADAWNDay One Biopharmaceuticals$131.16M4.95N/AN/A$4.99 per share1.28DCPHDeciphera Pharmaceuticals$174.91M12.65N/AN/A$4.38 per share5.84LGNDLigand Pharmaceuticals$167.13M16.29$1.63 per share86.57$43.95 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$36.14M-$1.36N/AN/AN/AN/A-32.07%-30.91%8/8/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/29/2025 (Estimated)DCPHDeciphera Pharmaceuticals-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/ALGNDLigand Pharmaceuticals-$4.03M-$7.120.0038.04N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)Latest DCPH, LGND, DAWN, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025BLTEBelite Bio-$0.42N/AN/AN/AN/AN/A8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A7/29/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35N/AN/AN/A$35.55 millionN/A5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A24.3124.31DAWNDay One BiopharmaceuticalsN/A10.6210.55DCPHDeciphera PharmaceuticalsN/A4.193.94LGNDLigand PharmaceuticalsN/A5.275.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%DAWNDay One Biopharmaceuticals87.95%DCPHDeciphera Pharmaceuticals70.96%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%DAWNDay One Biopharmaceuticals6.20%DCPHDeciphera Pharmaceuticals4.67%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionableDCPHDeciphera Pharmaceuticals30086.48 million82.44 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableDCPH, LGND, DAWN, and BLTE HeadlinesRecent News About These CompaniesBank of New York Mellon Corp Sells 3,421 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 21 at 3:26 AM | marketbeat.comNew York State Common Retirement Fund Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 19 at 4:22 AM | marketbeat.comJackson Creek Investment Advisors LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 18, 2025 | marketbeat.comStocks Showing Rising Market Leadership: Ligand Pharmaceuticals Earns 84 RS RatingJuly 18, 2025 | msn.comLigand Pharmaceuticals Stock Earns 84 RS RatingJuly 17, 2025 | msn.comJ&J boosts full-year outlook on forex tailwinds and operational performanceJuly 16, 2025 | msn.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High - Still a Buy?July 16, 2025 | marketbeat.comLigand Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS RatingJuly 15, 2025 | msn.comCenterBook Partners LP Purchases 44,760 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 15, 2025 | marketbeat.comRice Hall James & Associates LLC Sells 7,704 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 14, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 14, 2025 | marketbeat.comStephens Investment Management Group LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 13, 2025 | marketbeat.comLigand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - NasdaqJuly 12, 2025 | nasdaq.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 SharesJuly 12, 2025 | insidertrades.comInsider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)July 11, 2025 | gurufocus.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in StockJuly 11, 2025 | marketbeat.comLigand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | BenzingaJuly 11, 2025 | benzinga.comLigand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMIJuly 10, 2025 | finanznachrichten.deLigand Partner Pelthos Therapeutics Launches ZELSUVMI™July 10, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What HappenedJuly 9, 2025 | marketbeat.comCalamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCPH, LGND, DAWN, and BLTE Company DescriptionsBelite Bio NASDAQ:BLTE$61.30 +0.38 (+0.62%) Closing price 07/21/2025 04:00 PM EasternExtended Trading$60.94 -0.36 (-0.59%) As of 07/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Day One Biopharmaceuticals NASDAQ:DAWN$6.40 0.00 (0.00%) Closing price 07/21/2025 04:00 PM EasternExtended Trading$6.44 +0.04 (+0.70%) As of 07/21/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Deciphera Pharmaceuticals NASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Ligand Pharmaceuticals NASDAQ:LGND$141.12 +2.02 (+1.45%) Closing price 07/21/2025 04:00 PM EasternExtended Trading$141.20 +0.08 (+0.06%) As of 07/21/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Domino’s Delivers Another Discounted Entry for Income Investors TSLA Earnings Week: Can Tesla Break Through $350? Analysts See Upside in These 5 Stocks That Just Raised Dividends MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Kinder Morgan: At the Hotspot of the Natural Gas Revolution Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
